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MMP-2 geno-phenotype is prognostic for colorectal cancer
survival, whereas MMP-9 is not
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The prognostic significance of single-nucleotide polymorphisms (SNPs) and tumour protein levels of MMP-2 and MMP-9 was
evaluated in 215 colorectal cancer patients. Single-nucleotide polymorphism MMP-2 1306T and high MMP-2 levels were significantly
associated with worse survival. Extreme tumour MMP-9 levels were associated with poor prognosis but SNP MMP-9 1562C4T was
not. Tumour MMP levels were not determined by their SNP genotypes.
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Enhanced tumour matrix metalloproteinase (MMP) levels have
been correlated to decreased patients’ survival in various types of
cancer (Sienel et al, 2003; Pellikainen et al, 2004; Kubben et al,
2006b; Hilska et al, 2007; de Vicente et al, 2007). Next to sheer
degraders of extracellular matrix, MMPs are presently regarded as
general molecular switches in the microenvironment (Overall and
Blobel, 2007). For instance, MMPs function as major regulators of
tumour growth by catalysing the release or activation of growth
factors, activation or shedding of membrane receptors, or cleavage
of matrix/membrane-bound substrates involved in cell prolifera-
tion (Cauwe et al, 2007). A subgroup of MMPs, the gelatinases
(MMP-2 and MMP-9), have been particularly implicated in
progression, angiogenesis and metastasis of various cancer types
(Turpeenniemi-Hujanen, 2005). In the present study, we evaluated
the association between, and the prognostic relevance of tissue
protein levels of MMP-2 and MMP-9 and their gene promoter
single-nucleotide polymorphisms (SNPs) in a cohort of 215 Dutch
colorectal cancer patients.
MATERIALS AND METHODS
Patients and study design
Representative, nonnecrotic samples of cancer tissue were
collected from 215 patients with colorectal cancer, operated in
the Leiden University Medical Centre (December 1983–September
1991). Tissues were snap-frozen and stored at  701C. Clinical data
and follow-up were available for at least 10 years. Macroscopic and
microscopic parameters were obtained from the pathology reports.
The study was performed according to the instructions and
guidelines of the LUMC Medical Ethics Committee.
Tissue preparation and protein concentration
Tissues were homogenised in 0.1 M. Tris-HCL (pH 7.5) with
0.1% (v/v) Tween 80 buffer and centrifuged twice all at 41C, as
described before (Sier et al, 1991), the protein concentrations
were determined (Lowry et al, 1951) and the supernatants were
aliquoted and stored at  701C. Storage-induced degradation of
MMP-2 and MMP-9 was checked by western blots and gelatin
zymography prior to ELISA measurements (Sier et al, 1996).
Determination of MMP-2 and MMP-9 in tissue
homogenates
The MMP-2 and MMP-9 levels were determined by previously
described ELISAs (Gao et al, 2005). Polyclonal anti-MMP-2 or
monoclonal anti-MMP-9 antibodies were used as catching anti-
body, incubated with appropriately diluted samples (o/n, 41C), and
polyclonal anti-MMP-2/biotin-labelled goat anti-rabbit-IgG and
biotin-labelled polyclonal anti-MMP-9 antibodies for immune-
detection combined with avidin-peroxidase and the 3,30,5,50-
tetramethyl benzidine/H2O2 substrate solution, and the absorption
was read at 450nm. Sample MMP concentrations were calculated
from standard curves and expressed in ng per mg protein.
Single-nucleotide polymorphism analysis
Tissue DNA was isolated using the salting out method (Miller et al,
1988). Single-nucleotide polymorphism (SNP) analysis for
MMP-2 1306C4T and MMP-9 1562C4T was performed by tetra-
primer ARMS PCR, involving four oligonucleotide primers but no
restriction enzymes, or RFLP-PCR, as described earlier (Meijer
et al, 2006; Kubben et al, 2006a).
Statistical analysis
Statistical analyses were performed using SPSS 12.0 Statistical
Package (2004; SPSS Inc., Chicago, IL, USA). Expression differ-
ences between groups were calculated using the Mann–Whitney’s
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sU-test. Log-rank statistics was used for optimal cutoff point
analysis. Hardy–Weinberg’s analysis was performed using w
2 or
Fisher’s exact test to examine differences in the distribution of
alleles and genotypes. Correlations between parameters were
according to Pearson or Spearman, where appropriate. Overall
survival curves were according to Kaplan and Meier. Univariate
and multivariate survival analyses were performed using the Cox’s
proportional hazards method. P-values p0.05 were considered
significant.
RESULTS
The genotype distributions of the SNPs for MMP-2 and MMP-9
in 215 colorectal cancer patients are shown in Table 1. The
distribution of the polymorphisms in the patients was according to
the predicted Hardy–Weinberg’s distribution. Both SNPs showed
a weak but significant association with TNM stage (Table 1) and
MMP-2 1306C4T also with survival (Figure 1A). All other
clinicopathological parameters did not show an association with
either SNP MMP-2 1306C4T or MMP-9 1562C4T, and the latter was
also not associated with survival (Figure 1B).
The protein levels of MMP-2 (median 10.6; range: 0.0–76.6ng
per mg protein) and MMP-9 (median 37.3; range: 0.5–201.9ng per
mg protein) in the colorectal carcinomas were found not to be
related to any of the clinicopathological parameters, although for
MMP-2 a stepwise increase with TNM stage was discernable (not
shown). For the survival analysis, an optimised cutoff point value
was identified for the tumour MMP-2 level (18.5ng per mg protein,
LR 5.07, P¼0.024, Figure 2A). The same approach for MMP-9
resulted in two differently oriented cutoff points; a low MMP-9
value (11.2ng per mg protein, LR 9.18, P¼0.010) and a high value
(125.0ng per mg protein, LR 5.31, P¼0.021), both associated with
poor prognosis (Figure 2B).
The MMP-2 and MMP-9 protein levels in the colorectal cancer
homogenates did not correlate with their respective SNP
genotypes. The median values for MMP-2 1306C4T were 10.9, 9.5
and 11.6ngmg
 1 for genotypes CC, CT and TT, respectively. Even
an apparent enhancement of MMP-9 protein associated with the
TT genotype of SNP MMP-9 1562C4T in tumours did not reach
significance (CC/CT vs TT, medians 36.5/26.3 vs 44.4ngmg
 1,
P¼0.28).
Univariate Cox’s survival analyses confirmed the association of
the MMP-2 SNP and the protein levels of MMP-2 and MMP-9 with
survival (Table 2). Multivariate analysis against the prognosis-
associated parameters gender, age and TNM classification showed
that the MMP-2 SNP was independently associated with survival,
whereas the tumour protein levels of MMP-2 just lost and MMP-9
completely lost their significance.
DISCUSSION
MMP-2 and MMP-9 are proteinases implicated in cancer progression.
We showed previously that high tumour levels of MMP-2
in gastric carcinomas were consistently associated with a worse
survival (Sier et al, 1996; Kubben et al, 2006b). For enhanced
MMP-9 levels, the relation with survival was more ambivalent
(Kubben et al, 2006b, 2007). Also in our present cohort of
colorectal carcinoma patients, we found that MMP-2 and MMP-9
levels within the tumours are of significance to survival. The cutoff
point analysis showed a broad range of MMP-2 levels with a
significant and unidirectional relation with survival outcome: high
tumour MMP-2 levels are unfavourable for the patients’ prognosis.
Our ELISA-derived MMP-2 data correspond very well with a recent
immunohistochemical study in a group of 351 colorectal cancer
patients, showing that high expression of MMP-2 in malignant
epithelium as well as in the surrounding stroma was associated
with reduced survival (Hilska et al, 2007). Similar analysis on our
tumour MMP-9 data revealed that not only patients with the
highest, but also those with the lowest levels had a worse survival
Table 1 Genotype distribution of single-nucleotide polymorphisms
(SNPs) for MMP-2 and MMP-9 in 215 colorectal carcinoma patients
compared with the expected Hardy–Weinberg distribution (H-W)
SNP All
TNM stage*
genotype H-W patients 1234
MMP-2 1306C4T (%) % (N) % (N) % (N) % (N) % (N)
CC 55.4 54.4 (117) 69.4 (25) 57.1 (48) 52.2 (35) 32.1 (9)
CT 38.1 40.0 (86) 27.8 (10) 40.5 (34) 41.8 (28) 50.0 (14)
TT 6.6 5.6 (12) 2.8 (1) 2.4 (2) 6.0 (4) 17.9 (5)
MMP-9 1562C4T
CC 69.7 71.2 (153) 83.3 (30) 70.2 (59) 73.1 (49) 53.6 (15)
CT 27.6 24.7 (53) 11.1 (4) 28.6 (24) 23.9 (16) 32.1 (9)
TT 2.7 4.1 (9) 5.6 (2) 1.2 (1) 3.0 (2) 14.3 (4)
MMP¼matrix metalloproteinase *w
2values for TNM stage distribution of MMP-2
and MMP-9 were, respectively, 15.9 (P¼0.01) and 14.9 (P¼0.02).
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Figure 1 Kaplan–Meier’s 10-year survival curves of 215 colorectal cancer patients grouped by their genotype for SNP MMP-2 1306C4T (A) and
MMP-9 1562C4T (B). The total number of patients and the deceased patients (w) are indicated per subgroup.
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sthan patients with intermediate levels. Duality of tumour MMP-9
levels with respect to survival has been recognised before in
immunohistochemistry-based studies. For example, extensive
MMP-9 staining in ovarian cancer cells was associated with a
longer survival, as opposed to a shorter survival with a higher
stromal expression of MMP-9 (Sillanpaa et al, 2007). Earlier
morphometric studies indicated that the degree of MMP-9
expression in tumour-associated lymphocytes, macrophages and
neutrophils was inversely associated with invasion and metastasis
in colorectal cancer (Takeha et al, 1997). These observations are
relevant to our findings because a low level of MMP-9 in the
tumour homogenates might indicate a lack of infiltration of the
tumours with MMP-9 containing leukocytes, known to exert
anticancer effects (Nielsen et al, 1996; Owen et al, 2004), leading to
an adverse prognosis. In addition, MMP-9-mediated cleavage
of extracellular matrix components is also known to generate
antiangiogenesis inhibitors like angiostatin (Patterson and
Sang, 1997). Low MMP-9 expression in the tumour, leading
to insufficient production of antiangiogenic factors, could also
contribute to the worse prognosis of these patients (Pozzi et al,
2002). However, MMP-9 has a wide range of substrates,
including various growth factors and several types of collagen,
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Figure 2 Optimal cutoff point analysis and corresponding Kaplan–Meier’s 10-year survival curves for MMP-2 (A) and MMP-9 (B) in tumour tissue
homogenates from 215 colorectal cancer patients. The optimal cutoff points are indicated with arrows. In the survival curves, the total number of patients
and the deceased patients (w) are indicated per subgroup.
Table 2 Univariate and multivariate Cox’s proportional hazard 10-year survival analysis of 215 colorectal cancer patients
Univariate Multivariate
n HR CI 95% P HR CI 95% P
Parameter
Gender F vs M 91–124 1.363 0.973–0908 0.071 1.362 0.973–1.908 0.072
Age o65 years 4 73–142 2.123 1.448–3.113 0.000 2.390 1.625–3.516 0.000
TNM 1/2 vs 3/4 120–95 2.316 1.662–3.228 0.000 2.548 1.822–3.564 0.000
Localisation Right vs rest 75–140 1.023 0.726–1.442 0.896 Not included
Diameter o5cm4 92–123 1.310 0.936–1.834 0.116 Not included
Differentiation Good vs rest 38–174 1.129 0.789–1.614 0.506 Not included
MMP proteins
MMP-2 o18.5ngmg
 14 158–56 1.504 1.048–2.158 0.027 1.417 0.982–2.043 0.062
MMP-9 11.2–125 166 1.000
o11.2 34 1.526 1.004–2.319 0.048 0.787 0.516–1.201 0.266
4125 14 2.135 1.171–3.895 0.013 1.109 0.561–2.189 0.766
MMP SNPs
MMP-2 CC/CT vs TT 203–12 1.471 1.079–2.006 0.015 1.395 1.019–1.911 0.038
MMP-9 CC/CT vs TT 206–9 1.239 0.847–1.813 0.270 1.114 0.757–1.638 0.584
CI¼confidence interval; HR¼hazard ratio; MMP¼matrix metalloproteinase. Multivariate analysis was performed by adding every single MMP-related parameter to the
dichotomised, prognosis-associated clinicopathological parameters gender, age and TNM stage. Entries in bold indicate significant, or in case of MMP-2 almost significant P-values.
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swhich after cleavage contribute to the process of invasion,
angiogenesis and metastasis of tumours, explaining why high
tumour levels of MMP-9, in general, are associated with a poor
prognosis.
Differences in expression of metalloproteinases might, in part,
be explained by genotypic variation. Because the investigated SNPs
of MMP-2 and MMP-9 are located in the promoter region of the
gene, a correlation between polymorphism and protein expression
might be expected. The C-T transition at the  1306 position of
the MMP-2 gene promoter prevents binding of the stimulating Sp1
transcription factor, whereas a change at the  1562 position of the
MMP-9 gene decreases binding of a repression factor (Zhang et al,
1999; Price et al, 2001). In vitro MMP-2 expression levels by colon
cancer cell lines containing the CC genotype were indeed higher
compared with cells with the CT genotype (Xu et al, 2004). In our
cohort of patients, however, we found no relationship between
MMP-2 and MMP-9 polymorphisms and the tumour protein levels,
likely caused by the complicated regulatory posttranslational
mechanisms for proteinases in multicellular tumour tissues.
Nevertheless, we did find significant associations between
MMP-2 1306C4T and TNM stage and survival, that is, worse
prognosis in patients with the TT genotype. This association with
the outcome of the patients support the recent confirmation of
MMP-2 as one of the candidate cancer genes (CAN genes) by the
number and nature of mutations and pathways in colorectal cancer
(Sjo ¨blom et al, 2006). Our results for SNP MMP-9 1562C4T
correspond well with data from Asiatic patients (Xu et al, 2007),
indicating that this polymorphism is not directly involved in the
process of colorectal carcinogenesis.
Summarising, we showed that MMP-9, mechanistically probably
the most interesting of the gelatinases, is not a likely candidate as a
simple prognostic indicator. Despite the absence of a correlation
between promoter-located SNP  1306C4T in the MMP-2 gene
with tumour MMP-2 levels, both parameters were significantly
associated with survival, indicating MMP-2 as a consistent
independent prognostic factor in colorectal cancer.
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